Benzinga | Jul 21, 2020 06:04AM EDT

Cognizant Says Shared Investigator Platform For Life Sciences 'Reaches Major Milestone in Accelerating Drug Discovery'

More than 100,000 Life Sciences Researchers, Clinicians and Professionals in 84 Countries Utilizing Innovative SaaS Solution to Help Speed New Drug Therapies to Market

TEANECK, N.J., July 21, 2020 /PRNewswire/ -- Cognizant (NASDAQ:CTSH) announced that its Shared Investigator Platform (SIP), a life sciences Software as a Service (SaaS) solution, has reached a new milestone of over 100,000 users in 84 countries. The platform has become increasingly critical to progressing clinical trials as prevailing social distancing norms have significantly curtailed in-person collaboration. Many of the companies utilizing the Shared Investigator Platform are working to accelerate COVID-19 therapies through virtual clinical trial processes.